The earnings call reflects a strong performance by ADMA Biologics with significant revenue growth, successful strategic initiatives, and promising advancements in R&D. While there are challenges related to growth guidance and payer dynamics, the positive developments in yield enhancement, market penetration, and infrastructure expansion outweigh these concerns.

Company Guidance -

Q3 2025

During the ADMA Biologics Second Quarter 2025 Financial Results and Business Update Conference Call, the company provided robust guidance, highlighting significant financial and operational achievements. Total revenue for the quarter reached $122 million, reflecting a 29% year-over-year growth when adjusting for a nonrecurring Medicaid rebate accrual reversal. Adjusted net income and adjusted EBITDA grew approximately 85% and 59% year-over-year, respectively. The company reaffirmed its financial guidance for 2025, expecting total revenue of $500 million or more, adjusted EBITDA of at least $235 million, and adjusted net income of $175 million or more. Looking ahead to 2026, ADMA anticipates at least $625 million in total revenue, adjusted EBITDA of $340 million or more, and adjusted net income of at least $245 million. The company also highlighted the successful implementation of an FDA-approved yield enhancement process, which is expected to increase bulk IG output by 20% or greater, driving gross margin expansion from early 2026. Additionally, ADMA completed a debt refinancing with JPMorgan, securing a $300 million credit facility to lower borrowing costs and enhance financial flexibility. The acquisition of a new facility near their Boca Raton campus is expected to support future growth by expanding operating capacity and infrastructure.

Substantial Revenue Growth

Total revenues reached $122 million, representing a 29% year-over-year growth on an underlying basis, excluding the nonrecurring Medicaid rebate accrual reversal.

ASCENIV Utilization and Market Penetration

ASCENIV utilization reached record highs, with expanded availability and positive feedback from the medical community, indicating strong market potential and demand.

Yield Enhancement Process

The FDA-approved yield enhancement process is underway, achieving a 20% or greater increase in bulk IG output, expected to drive meaningful gross margin expansion.

Debt Refinancing

Completed a JPMorgan-led debt refinancing, lowering borrowing costs and enhancing liquidity, providing additional financial flexibility for long-term growth.

Infrastructure Expansion

Acquired a facility and adjacent land near the Boca Raton campus, expected to support growth through expanded cold storage, warehousing, and potential manufacturing space expansion.

R&D Progress

Initiated studies on SG-001, a potential $300-$500 million annual revenue opportunity, with promising preclinical results and patent protection through at least 2037.

ADMA Biologics (ADMA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ADMA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.15 / -	0.163	―	―	―
Aug 06, 2025	2025 (Q2)	0.14 / 0.15	0.142	3.52% (<+0.01)	―
May 07, 2025	2025 (Q1)	0.15 / 0.14	0.089	52.81% (+0.05)	―
Mar 03, 2025	2024 (Q4)	0.15 / 0.14	-0.08	276.25% (+0.22)	―
Nov 07, 2024	2024 (Q3)	0.13 / 0.16	0.01	1530.00% (+0.15)	―
Aug 08, 2024	2024 (Q2)	0.08 / 0.14	-0.018	888.89% (+0.16)	―
May 09, 2024	2024 (Q1)	0.06 / 0.09	-0.03	396.67% (+0.12)	―
Feb 28, 2024	2023 (Q4)	0.03 / -0.08	-0.06	-33.33% (-0.02)	―
Nov 08, 2023	2023 (Q3)	>-0.01 / 0.01	-0.08	112.50% (+0.09)	―
Aug 09, 2023	2023 (Q2)	-0.03 / -0.02	-0.07	74.29% (+0.05)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ADMA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$18.54	$16.75	-9.65%
May 07, 2025	$23.61	$21.20	-10.21%
Mar 03, 2025	$15.83	$17.01	+7.45%
Nov 07, 2024	$19.72	$22.62	+14.71%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ADMA Biologics (ADMA) report earnings?

ADMA Biologics (ADMA) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is ADMA Biologics (ADMA) earnings time?

ADMA Biologics (ADMA) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ADMA EPS forecast?

ADMA EPS forecast for the fiscal quarter 2025 (Q3) is 0.15.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing